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Abstract
Although both physiological hypertrophy (PHH) and pathological hypertrophy (PAH) of the heart have similar
morphological appearances, only PAH leads to fatal heart failure. In the present study, we used RNA sequencing (RNA-
Seq) to determine the transcriptomic signatures for both PHH and PAH. Approximately 13–20 million reads were obtained
for both models, among which PAH showed more differentially expressed genes (DEGs) (2,041) than PHH (245). The
expression of 417 genes was barely detectable in the normal heart but was suddenly activated in PAH. Among them, Foxm1
and Plk1 are of particular interest, since Ingenuity Pathway Analysis (IPA) using DEGs and upstream motif analysis showed
that they are essential hub proteins that regulate the expression of downstream proteins associated with PAH. Meanwhile,
52 genes related to collagen, chemokines, and actin showed opposite expression patterns between PHH and PAH. MAZ-
binding motifs were enriched in the upstream region of the participating genes. Alternative splicing (AS) of exon variants
was also examined using RNA-Seq data for PAH and PHH. We found 317 and 196 exon inclusions and exon exclusions,
respectively, for PAH, and 242 and 172 exon inclusions and exclusions, respectively for PHH. The AS pattern was mostly
related to gains or losses of domains, changes in activity, and localization of the encoded proteins. The splicing variants of 8
genes (i.e., Fhl1, Rcan1, Ndrg2, Synpo, Ttll1, Cxxc5, Egfl7, and Tmpo) were experimentally confirmed. Multilateral pathway
analysis showed that the patterns of quantitative (DEG) and qualitative (AS) changes differ depending on the type of
pathway in PAH and PHH. One of the most significant changes in PHH is the severe downregulation of autoimmune
pathways accompanied by significant AS. These findings revealed the unique transcriptomic signatures of PAH and PHH
and also provided a more comprehensive understanding at both the quantitative and qualitative levels.
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Introduction
Cardiac hypertrophy involves multiple cellular signaling
pathways and is a compensatory response to a variety of stimuli.
While physiological hypertrophy (PHH) is associated with
eccentric growth, pathological hypertrophy (PAH) is characterized
by eccentric or concentric growth, depending on whether it occurs
in response to pressure or volume overload [1]. Initially, PAH
compensates for increased workload; however, its progression
generally leads to detrimental remodeling and cardiac dysfunction
[1]. In contrast, exercise training-induced PHH is a favorable
response to physical activity; it is characterized by increased left
ventricular volume and a proportional increase in wall thickness
and mass [2]. However, the underlying molecular mechanisms
responsible for the different types of hypertrophic adaptations
remain to be elucidated.
Thus far, several genome-scale studies of cardiac hypertrophy
have been conducted to determine comprehensive signatures by
using the microarray method [3–6]. However, this method has
several limitations such as spatial bias, uneven probe properties,
low sensitivity, and dependency on the probes spotted [7–9].
Therefore, complete transcriptomic profiling of the different types
of cardiac hypertrophy has not been performed. RNA sequencing
(RNA-Seq) is a revolutionary alternative that can overcome the
limitations of the microarray technique, enabling the sequencing
of considerably large sequences in a short time. In addition, unlike
microarrays, the RNA-Seq method has high reproducibility,
sensitivity, and capability for capturing the splicing variants.
In this study, we performed a detailed RNA-Seq study to
simultaneously elucidate both the quantitative and qualitative
signatures of PAH and PHH. Initially, we conducted both RNA-
Seq and microarray experiments to evaluate the efficacy of the
RNA-Seq method in studies of mammalian hearts. We found that
RNA-Seq provides considerably higher sensitivity, accuracy, and
reproducibility than the microarray method for cardiac analysis.
Therefore, the method of RNA-Seq was selected in the current
study for examining cardiac transcriptomic signatures in the
different hypertrophy models. Further system-level approaches
using the differentially expressed genes (DEGs) derived from the
PAH and PHH samples showed that the signaling pathways and
the expression of the genes involved in PAH are strikingly different
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35552from those of PHH. Notable differential transcriptome changes
were also observed in alternative splicing (AS) patterns in the
hypertrophy models.
Taken together, in this RNA-Seq study, we showed distinct
transcriptomic signatures related to PHH and PAH, which could
provide useful insights into understanding the mechanisms
underlying PHH and PAH.
Results
Animal models and high-throughput sequencing
In order to study the transcriptomic signatures of cardiac
hypertrophy, we generated 2 different mouse models for cardiac
hypertrophy. C57BL/6J mice were subjected to swim-training and
pressure overload by trans-aortic constriction (TAC) to produce
models of PHH and PAH, respectively. In both models, the hearts
were significantly enlarged as evidenced by the heart weight to
body weight (HW/BW) ratio (p,0.01) (Figure S1A). The extent of
hypertrophy was determined by quantitative real-time PCR (qRT-
PCR) for 5 hypertrophy markers: Nppa, Nppb, Myh7, Acta1, and Pln.
Although the hypertrophied hearts had similar appearances, the
expression levels of the markers significantly differed between the
PHH and PAH mice. In PAH mice, Nppa, Nppb, Myh7, and Acta1
were considerably upregulated, while Pln was downregulated
(Figure S1B). However, in PHH mice, Nppa was upregulated, Acta1
was downregulated, and the Nppb, Myh7, and Pln expression levels
remained unchanged. The expression levels of these markers in
PHH and PAH are comparable with those reported in previous
studies [10–14].
For both models, we performed RNA-Seq by using an Illumina
Genome Analyzer II (GA-II), and approximately 22–26 million
reads were obtained. From these reads, low-quality reads were
eliminated, resulting in 13–20 million reads (equal to 60–70% of
the total reads). In total, 12–13 and 7–8 million reads were aligned
to the mouse genome (mm9) for PAH and PHH, respectively
(Table S1). The numbers of reads for genes were further
normalized to ‘‘reads per kilobase of exon model per million
mapped reads’’ (RPKM); thus, the values were considered the final
expression levels for each gene [15]. According to Mortazavi et al.
[15], a single gene copy is equivalent to 1,3 RPKM, depending
on the cell type [15]. We also observed at least 2 RPKM genes
expressed in the heart (i.e., Bcl2, Myc, Pex1, and Eya2). Therefore,
we discarded the genes with fewer than 2 RPKM to reduce false
positives. Finally, the analysis showed that 10,233–10,573 genes
were expressed in the hearts (Figure 1). The gene expression
profiles derived from RNA-Seq were further compared to the
profiles by using the microarray technique. To efficiently compare
the techniques, the RPKM values of genes were converted into the
logarithmic value of ‘‘reads per kilobase of exon model per billion
mapped reads’’ (RPKB). Although highly consistent profiles were
obtained for each profiling method (R
2,0.96–0.98), the correla-
tions between techniques were significantly lower at approximately
0.62, indicating technological differences (Figure S2). As shown in
Figure S3, RNA-Seq exhibited much higher sensitivity than the
microarray technique, as evidenced by the significantly increased
number of DEGs (n=2,041 vs. 891). To verify the accuracy of the
2 techniques, we performed qRT-PCR for 51 genes. The
expression patterns were consistent for RNA-Seq and qRT-PCR
(R
2=0.86–0.89), in contrast with the results for the microarray
method (R
2=0.67). These results suggest that RNA-Seq consis-
tently provides considerably higher sensitivity and accuracy than
the microarray method [16,17].
DEGs and network analysis
DEGs associated with PAH and PHH were analyzed using the
following criteria: p,0.05 (Student’s t-test), |fold change|$1.5,
and expression level $2 RPKM. The analysis showed 2,041 and
245 DEGs for PAH and PHH, respectively (Figure 1B). In
addition to the striking difference in the number of DEGs between
the 2 types of hypertrophy, the DEG patterns were clearly
different. For instance, 70% of all DEGs (1,429 genes) were
upregulated in PAH, whereas 73% were downregulated in PHH
(179 genes). Interestingly, the expression of 417 genes (29%) was
barely detectable in normal hearts (i.e., RPKM,2) but consider-
ably increased in PAH. The remarkable features of these genes
were determined from the gene networks inferred by Ingenuity
Pathway Analysis (IPA, http://www.ingenuity.com). According to
the top-scoring network, the abundant genes were cell cycle
regulators such as E2F transcription factor 1 (E2f1), forkhead box
M1 (Foxm1) and polo-like kinase 1 (Plk1) (Figure 2A). The
expression levels of E2f1, Foxm1 and Plk1 in PAH were clearly
distinguishable from those in PHH, as shown in Figure 2B. While
the basal expressions of E2f1, Foxm1 and Plk1 were extremely low
(RPKM,2), the expressions of the genes were 5.3,8.9 times
greater in PAH.
We further analyzed the 1000 bp upstream sequence of these
417 genes to identify transcription factor (TF) binding motifs using
MEME [18]. The putative binding motifs for FOXM1
(p=1.9610
25) and PU.1 (p=4.8610
221) were significantly
enriched in the 1,000 bp upstream of the genes encoding cell
cycle regulators (Figure 2C). The strong expression of FOXM1
(7.7 fold greater in PAH than sham) and the known downstream
targets (Figure 2D) suggest that it plays a critical role in
pathogenesis. FOXM1 is known to be important for cardiac
development [19], however, there is no report regarding the role
of FOXM1 in cardiac hypertrophy. The binding motif for PU.1
was also highly enriched in the upstream region. The expression of
Sfpi1 encoding PU.1 remained moderate in the basal state but
increased significantly by 2.33 fold (14.46 RPKM) in PAH,
suggesting its involvement in pathogenesis. Although Wontakal et
al. recently reported that PU.1 ChIP-Seq peaks are abundant
within the upstream regions of cell cycle regulators in erythroid
cells [20], the specific roles of PU.1 in the cell cycle or cardiac
hypertrophy remain unknown. Highly conserved motifs for
PITX2 and PAX were identified, but the expression levels of
Pitx2 and Pax encoding PITX2 and PAX, respectively, were
extremely low in PAH (data not shown).
We further analyzed 52 genes that were oppositely regulated in
the 2 hypertrophy models. The top-scoring networks for 52 genes
were highly enriched with genes encoding collagens, chemokines,
and actin (Figure S4A). To predict the master TFs for 52 genes, we
analyzed the enriched motifs within 1,000 bp upstream of the
genes. We identified the strong enrichment of two MAZ consensus
motifs, GGGAGGG (p=1.0610
210) and CCCTCCC [21,22]
(Figure S4B). According to a recent finding, MAZ may regulate
the expression of muscle specific genes via these consensus motifs
[23]. Taken together, our study suggests that MAZ is an important
TF for both types of cardiac hypertrophy.
Analysis of exon variants
AS is an important regulatory mechanism in gene expression; it
generates considerable versatility at the post-transcriptional level
and accounts for proteome complexity. Recent studies have
estimated that 75–92% of human genes undergo AS events
[24,25]. In the heart, several genes (e.g., Tnnt2, Camk2d, Ncam, and
Pdlim5) are reported to undergo AS during cardiac development
[26–29]. However, few AS events have been reported in adult
RNA-Seq in Hypertrophy
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exclusions in terms of known alternative exon variants on the basis
of a UCSC ‘‘knownAlt’’ (Fisher’s exact test, p,0.05; Bayesian
error rate, e#0.1). As shown in Figure S5A, we identified 317 and
196 exon inclusions and exclusions, respectively, in PAH, and 242
and 172 exon inclusion, respectively, in PHH. Alternative
promoter usage (43% and 37% for PAH and PHH, respectively)
followed by cassette exons (26% and 24% for PAH and PHH,
respectively) were the most abundant types of AS events (Figure
S5B, C).
To determine which functions are affected by AS events, we
searched previous in-depth studies on exon variants. According to
the previous studies (Table 1), the biological properties altered by
AS were classified into the following categories: (1) domain gain or
loss, (2) activity change, and (3) localization. The most abundant
feature was gains or losses of domains, as observed in Limk2, Enah,
Sox17, Aak1, Itsn1, and Plec1. The Lim, PDZ, and clathrin-binding
domains disappeared in Limk2t and Aak1s during PAH [30,31].
The domain variants for EPS15 homology, Src homology, and
actin-binding domains were observed in Itsn1 and Plec1 during
PAH. However, the exon encoding the high-motility group
(HMG) domain of Sox17 was included in PHH (Table 1).
Differential activity or sensitivity was predicted in Cav1a, Pde1c,
and Ncoa1 on PI3K/Akt (for Cav1a), Ca
2+, cAMP, cGMP (for
Pde1c), and thyroid hormone (for Ncoa1) [32–34]. In addition, AS
influenced localization in Sorbs1, Ehmt2, and Plec1 (Table 1) [35–
37].
Experimental confirmation of exon variants
To validate the exon variants, we designed RT-PCR assays. 10
exon variants for 8 genes were selected for validation. The
expression of the exon variants and their constitutive exons was
compared. The results confirmed that the exon variants
corroborated the RT-PCR results (Figure 3). To confirm the
exon variants associated with the different types of cardiac
hypertrophy, the isoform analysis was performed using NEUMA
[38]. For the Fhl1 gene, both quantitative and qualitative changes
were simultaneously observed, i.e., its expression increased by 3.5
fold, and the Fhl1-3 isoform specifically increased during PAH.
Although the most abundant isoform was Fhl1-1, Fhl1-3, which
encoded additional 16 amino acids, increased with alternative
promoter usage. Similarly, alternative promoter usage was also
observed in Rcan1 isoforms. Along with the strong 2.97-fold
increase, the proximal promoter usage resulted in specific increase
of Rcan1-1, which produced slightly different N-terminal sequenc-
es. In the case of Ndrg2, differential cassette exon usage was
observed in PAH. Among the 2 isoforms of Ndrg2, the shorter
isoform excluding the exon at the 52,530,761,52,530,802 region
of chromosome 14, was significantly upregulated in PAH.
Quantitative reduction of ,30% was found in Ndrg2, suggesting
Figure 1. Summary of differentially expressed genes (DEGs) in pathological hypertrophy (PAH) and physiological hypertrophy
(PHH). (A) Venn diagrams to show the number of expressed genes detected at least once for each biological replicate of sham, TAC, sedentary and
exercise-training mouse models. (B) Comparisons of DEGs between the different mouse models. Genes having at least 2 RPKM value and differentially
expressed at (p,0.05, |log1.5 fold change (FC)|$1) were considered for comparisons.
doi:10.1371/journal.pone.0035552.g001
RNA-Seq in Hypertrophy
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isoforms of Synpo, relatively strong expression of the exon
positioning at 60,753,627,60,756,142 region of chromosome 18
was observed, contrary to the constant expression of the previous
exon (i.e., E4). The isoform analysis showed that the most
significantly increased isoform was Synpo-3. However, specific
activity of Synpo-3, which increased significantly in PAH, has not
yet been reported.
Although no isoform for Ttll1 has been reported in the UCSC
mouse genome database, we observed that the last exon of Ttll1
was strongly excluded, indicating the existence of isoforms. The
histograms for the reads mapped into Ttll1 and the significant
decrease in the expression of exons 10,11, as shown by RT-PCR,
also supported the possibility that Ttll1 has multiple isoforms in
PAH. We also identified the exon variants regulated in PHH.
Cxxc5 underwent an AS event in PHH, specifically alternative
Figure 2. Network of the genes turned on in PAH. (A) Top-scoring network derived from the 417 genes dramatically increased in PAH, despite
their extremely low expression (,2 RPKM) in either normal adult heart or exercise-trained heart. The red-colored nodes represent up-regulated
genes. (B) The histograms for the reads that were mapped by the UCSC isoforms of Plk1, Foxm1 and E2f1 in the different animal models. The blue
lines underneath represent UCSC gene structures and the boxes show the exons of the genes. Expression of the 3 genes is only dominant in TAC. (C)
The predicted motifs enriched in 1,000 bp upstream of 417 genes. The motifs shown on the bottom were predicted by MEME and the motifs shown
above are the consensus motifs for the TFs (FOXM1 and PU.1). Y-axis indicates the amount of information at each position in the motif. The heatmaps
(unit: RPKM) show the expression levels of the predicted TFs in sham (Sh), TAC (T), Se (Sedentary) and E (exercise). (D) Degree of expression (unit:
RPKM) of the known targets of FOXM1 in the animal models are shown along with the previous evidence (PMID).
doi:10.1371/journal.pone.0035552.g002
RNA-Seq in Hypertrophy
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35552promoter usage for the gene. Among the 2 Cxxc5 isoforms derived
from the alternative promoters, the transcript from the distal
promoter increased significantly during exercise, in contrast to the
constant expression of the transcript with the proximal promoter.
These Cxxc5 isoforms are likely to produce the same proteins even
with different 59 UTRs, implying the possibility of post-
transcriptional regulation. Among the exon variants, hypertrophic
signal-specific regulation was apparent in Egfl7 and Tmpo.
According to the UCSC genome browser analysis, 3 different
alternative promoters were involved in the AS for Egfl7.
Significantly increased usage of the most distal promoter (i.e.,
Egfl7-1) was confirmed in PAH by RT-PCR; the usage of the
promoter decreased in PHH [39]. Signal-dependent splicing
regulation was also found in Tmpo. The inclusion of exon 6 in PAH
was experimentally confirmed by RT-PCR, suggesting the
relatively increased proportion of Tmpo-1 encoding TMPOb
[40]. The opposite splicing pattern (i.e., exclusion) was found in
PHH. The opposite regulation was also found at the quantitative
level, i.e., the expression decreased slightly and increased in PHH
and PAH, respectively. These findings suggest multilateral
regulation both in quantitatively and qualitatively according to
the hypertrophic signals.
Critical pathways involving DEGs and splicing variants
The critical pathways associated with DEGs and splicing
variants were investigated using 194 KEGG pathways [41]. The
pathways enriched with the up- or downregulated DEGs and
splice variants for PAH and PHH are shown in Figure 4.
The enrichment patterns for the pathways could be categorized
into 5 groups. Group I involved pathways for muscle contraction
and metabolism. Clear transcriptomic signatures were observed in
the genes involved in cardiac muscle contraction and various
metabolic processes (e.g., oxidative phosphorylation, fatty acid
metabolism, the TCA cycle, and pyruvate metabolism). The genes
were significantly downregulated only in PAH, with little AS.
However, there were neither quantitative nor qualitative changes
in PHH. Group II mainly involved pathways for immune function
and cell cycle: The common feature among p53 signaling, ECM,
cell cycle, leukocyte migration, Fcc R-mediated phagocytosis and
focal adhesion was the strong enrichment of up-regulated genes in
PAH. Among these, the quantitative changes in the genes involved
in ECM, Fcc-mediated phagocytosis and focal adhesion were
combined with the AS in PAH. The most dynamic regulation was
observed in ECM in that the gene exhibited distinguishable
expression patterns between PAH and PHH, along with
considerable AS in PAH. Group III mainly involved pathways
implicated in autoimmunity. In PHH, the most striking features
were the remarkable suppression of autoimmune systems such as
cell adhesion, antigen presentation, viral myocarditis, allograft
rejection, and autoimmune thyroid diseases. In PHH, the
autoimmunity genes were significantly downregulated and active
AS was seen. However, the same changes were not observed in
PAH. Transcriptomic suppression and AS were observed in the
major histocompatibility complex (MHC) in PHH. Group IV
involved pathways for cell signaling. It is notable that in PHH, the
major regulatory mechanisms for various signaling pathways,
splicesomes and gap junctions exhibited qualitative remodeling via
AS. For these pathways, quantitative changes were hardly detected
Figure 3. Experimentally verified isoforms alternatively spliced in PAH and PHH. (A) The histograms of mapped reads for 8 genes. The red
asterisks shown at UCSC isoforms (blue lines underneath) indicate the exons (shown as blue boxes) alternatively spliced in hypertrophic signal-
specific manners. The degree of expression is shown as vertical length. (B) Distribution of UCSC isoforms for the matching 8 genes characterized in
different hypertrophy models. Different distribution of isoforms in either PAH or PHH was analyzed using NEUMA. The average RPKM values are
shown with standard errors (N=3). (C) Experimental confirmation of exon variants for the matching 8 genes using RT-PCR. For each RT-PCR results,
the amplified regions with the specific primers are described. The detailed information for the primers used for the detection of the exons is available
in Table S2. Fhl1, Rcan1, Ndrg2, Synpo and Ttll1 were experimentally confirmed in PAH and the splicing pattern of Cxxc5 exon variants was confirmed
in PHH. For Egfl7 and Tmpo, the opposite splicing patterns were confirmed for both PAH and PHH. The isoform distributions of Ttll1 and Cxxc5 were
not analyzed, since the UCSC isoforms for Ttll1 is not reported and there were no mappable reads for Cxxc5-2. The exon numbers amplified are
indicated on the right. For instance, E5,6 means exon 5 and 6 were amplified with specific primers shown in Table S2. For Ndrg2, two isoforms
(E2,5, +E3 and E2,5, 2E3) were shown in the same gel.
doi:10.1371/journal.pone.0035552.g003
Figure 4. Critical pathways associated with DEGs and exon
variants changed in PAH or PHH. Significantly enriched pathways
(p,0.05) with at least 5 DEGs or 5 exon variants for PAH and PHH are
shown. Color intensity represents degree of enrichment (2log10[p-
value]). The significant pathways were categorized. (Group I) pathways
for muscle contraction and metabolism. (Group II) pathways mainly for
immune and cell cycle. (Group III) pathways for autoimmunity. (Group
IV) pathways for cell signaling. (Group V) pathways mainly for cardiac
diseases.
doi:10.1371/journal.pone.0035552.g004
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35552in PHH. In the case of endocytosis, remarkable qualitative
regulation was observed in both PAH and PHH, whereas there
was no significant quantitative change in either cardiac hypertro-
phic model. Interestingly, the splicing patterns and targets
involved in endocytosis were unique, depending on the hypertro-
phic signals. For example, exon 6 of Clta was a common splicing
target; it was excluded in PAH but included in PHH. Group V
mainly involved pathways related to cardiac diseases. Pathological
signatures were apparent in PAH with quantitative and qualitative
enrichment of pathways related to cardiovascular diseases such as
hypertrophic cardiomyopathy (HCM), arrhythmogenic right
ventricular cardiomyopathy (ARVC), and dilated cardiomyopathy
(DCM). For PHH, the significant changes via AS were apparent in
DCM and the actin cytoskeleton, suggesting that these pathways
are the critical targets for regulation as a result of hypertrophic
signals.
Discussion
While the enlargement of the heart in PHH and PAH appears
similar at the morphological level, the outcomes of the 2 types of
hypertrophy are strikingly different. PHH leads to a considerable
improvement in quality of life through increased oxidative
capacity and maximal cardiac output, whereas PAH is associated
with progressive deterioration of heart functions, ultimately
leading to fatal heart failure. Therefore, characterizing both
PHH and PAH at the molecular and systemic levels is essential for
identifying the critical signaling pathways leading to adaptation or
mal-adaptation. Thus far, the detailed mechanisms underlying the
progression of hypertrophic processes have not been elucidated. In
the present study, we used the RNA-Seq technique to profile near-
complete transcriptomes in both PHH and PAH.
The novel findings of this study are as follows: (1) The number
of DEGs was considerably higher in PAH than in PHH (8-folds
higher) (Figure 1). (2) We found that 417 silent genes were turned
on in PAH, whereas the expression of 52 genes was oppositely
regulated between PAH and PHH (Figure 1). (3) FOXM1 was
identified as a putative transcription factor involved in the
pathogenesis of PAH (Figure 2). (4) The 52 genes differentially
regulated between PAH and PHH are related to collagen, actin,
and chemokine and MAZ was identified as a putative TF for the
participating genes (Figure S4). (5) Substantial AS (both exon
inclusion and exclusion) leading to a gain or loss of domains as well
as changes in the activity and localization of the participating
proteins were identified from RNA-Seq data for both PAH and
PHH (Figure 3 and Table 1). (6) According to the multilateral
pathway analysis using RNA-Seq data, 5 different patterns
distinguishing PAH and PHH were found (Figure 4): group I
(includes pathways for muscle contraction and metabolism),
downregulated DEGs with mild AS in PAH; group II (mainly
involving pathways for immunity and cell cycle), upregulated
DEGs with considerable AS in PAH; group III (mainly involving
pathways implicated in autoimmunity), downregulated DEGs with
considerable AS in PHH; group IV (involving pathways for cell
signaling), considerable AS in PHH; and group V (mainly
involving pathways for cardiac diseases), upregulated DEGs with
considerable AS in PAH.
RNA-Seq vs. microarray
In the present study, we used RNA-Seq and microarray
methods in order to understand the transcriptomic signatures for
cardiac hypertrophy. The major advantages of RNA-Seq over
microarrays are its significantly improved detection accuracy,
ability to identify AS without probe dependency, and de novo
analysis of novel transcripts and long non-coding RNAs [42].
RNA-Seq also exhibited a considerably greater capacity to identify
DEGs (.40%), with considerably higher accuracy than micro-
arrays (Figure 1). This critical advantage helped us expand our
understanding, as exemplified by the significant enrichment of the
gap junction pathway in PAH. In the gap junction pathway, 3.3-
fold more DEGs (n=20) were observed with RNA-Seq than with
microarrays (n=6). Our prior knowledge regarding the involve-
ment of the gap junction pathway in cardiac hypertrophy further
indicates that RNA-Seq identifies DEGs much more accurately.
However, RNA-Seq has some limitations, including limited
software, bioinformatic algorithms, and standardization. For
example, the rational criteria defining gene expression have not
yet been standardized; therefore, the cutoff values for determining
background expression levels vary widely across studies (e.g., 95%
confidence level and .100 read count). Such variations cause
differences in results. Therefore, a sophisticated algorithm for
determining gene expression is a challenging issue that needs to be
addressed. In certain cases including some histone genes the
microarray method performed better than RNA-Seq. Genes that
were not detected by RNA-Seq exhibited common characteristics,
for example no polyadenylation in eukaryotes. These results are
due to the procedure for mRNA isolation, which involved oligo-
dT magnetic beads. Therefore, it is necessary to be careful when
comparing RNA-Seq with microarrays. Since no gene annotation
data in mouse mitochondria were present in the UCSC database,
we excluded the RNA-Seq reads of the mitochondrial genome.
From the RNA-Seq reads aligned to the mitochondrial chromo-
some, 13–15% of RNA-Seq reads were mapped to the
mitochondrial chromosome in sham, sedentary, and swim-trained
animal models; however only 9% of reads were mapped to the
mitochondrial chromosome in the TAC model mice (data not
shown).
Top-scoring Ingenuity networks for identifying critical
molecules involved in hypertrophy
The top-scoring Ingenuity network suggests that Foxm1 plays an
important role in the pathogenesis of PAH (Figure 2). Although
Foxm1 is known to be involved in tumorigenesis [43,44] and
cardiac development [19], its role in cardiac hypertrophy
remained unknown until now. Our prediction of Foxm1 as an
important TF for PAH is based on the remarkable sensitivity of
RNA-Seq as well as critical analysis of the network involved
(Figure 1). The mechanism leading to PAH by Foxm1 must be
related to cell cycle regulators such as Plk1 and E2F1. The tight
regulatory loops among genes, including Foxm1 and Plk1, have
already been identified in other animal models [45]. The results
also suggest a regulatory role of Sfpi1 encoding PU.1in the Foxm1-
Plk1 loop, since the putative binding motifs of PU.1 were found
upstream of these genes. In contrast to the results for Foxm1 and
Plk1, Sfpi1 is expressed in the adult heart, and its expression is
significantly elevated in PAH. The functional role of Sfpi1 in cell
cycle regulators has not been studied thus far, although its binding
targets were identified by Chip-Seq experiments [20].
We further analyzed 52 genes oppositely regulated in the 2
hypertrophy models (Figure S4). The network for these genes was
highly correlated with collagen, chemokine, and actin genes. To
predict the master TFs for 52 genes, we examined the enriched
motifs within 1,000 bp upstream of the genes and identified the
strong enrichment of the MAZ consensus motif, GGGAGGG
(p=1.0610
210) and CCCTCCC (p=6.6610
211) [23]; this result
supports the potential role of MAZ in the regulation of those
genes. Collectively, our study results predicted several critical
genes that may be involved in the pathogenesis of hypertrophy.
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Examples of alternative splicing in PAH and PHH
Compared with microarray, RNA-Seq could provide a great
advantage by enabling the simultaneous analysis of both DEG and
AS without platform dependency. With the aid of RNA-Seq, we
identified 470 and 387 genes containing known alternative exons
in PHH and PAH, respectively. Of these, we experimentally
confirmed AS for 8 genes, i.e., Fhl1, Rcan1, Ndrg2, Synpo, Ttll1,
Cxxc5, Egfl7, and Tmpo (Figure 3). Among them, Fhl1 exhibited
complicated expressional regulation, both quantitatively and
qualitatively. The Fhl1 gene encodes 3 different isoforms (Fhl1,
Fhl1b, and Fhl1c) as a result of AS. The results of the present study
indicate that in PAH, the use of the most proximal promoter,
which transcribes Fhl1, increases significantly. The distinct
functions of Fhl1 and Fhl1b and their roles in pathogenesis have
been reported previously [46–48]. In the case of Rcan1, 2 splice
variants, Rcan1-1 and Rcan1-4, have been reported thus far [49].
The transcription of the splicing variants is specifically regulated
by glucocorticoids [50], oxidative stress or Ca
2+ and calcineurin
[51]. Our results indicate that Rcan1-4 expression increases
specifically and strongly in PAH, suggesting the possible mediation
of calcineurin pathways in pathogenesis. Among the 2 known
isoforms of Ndrg2 (i.e., Ndrg2S and Ndrg2L), significant reduction in
Ndrg2L encoding the long form containing exon 3 is found in PAH
[52]. However, the biological significance of the insertion/removal
of 14 amino acids (i.e., EAELAARILLDQGQ) encoded by exon 3
has not yet been studied. Multilateral regulation at both
quantitative and qualitative levels was also apparent in Synpo.
The expression level of Synpo increased significantly along with the
strong inclusion of exon 4 in PAH. However, the isoform that
increased significantly in PAH has not been identified yet [53].
Ttll1 decreased significantly at the quantitative level in PAH. The
exclusion of the last exon implies qualitative regulation in Ttll1,
although UCSC isoforms has not been reported in mice [54]. We
found contrasting splicing patterns for Egfl7 and Tmpo depending
on the hypertrophic signals. Although there were no significant
quantitative changes in these 2 genes, their distinguishable splicing
patterns suggest that they are qualitatively regulated by each
stimulus.
The differential expression of splicing factors could regulate the
exon variants occurring in the hypertrophy models. Our analysis
indicates that the expression levels of 2 important splicing factors,
Ptbp1, which encodes pyrimidine tract-binding protein (PTB), and
A2bp1, which encodes ataxin 2-binding protein 1 (A2BP1, also
known as Fox1), were significantly altered in PAH. Consistent with
the previous report regarding post-transcriptional regulation in
PAH [55], we also observed significant upregulation of Ptbp1 (1.9-
fold change, p=0.00034) and downregulation of A2bp1 (0.34-fold
change, p=0.0014) in PAH. However, the detailed regulatory
mechanisms underlying the exon variants related to the 2 splice
factors remains to be elucidated.
Pathway analysis to distinguish PAH from PHH
The significance of our analysis of the RNA-Seq data to
distinguish between the 2 types of hypertrophy using both
quantitative and qualitative approaches is clearly shown in
Figure 4. Enriched KEGG pathways associated with the DEGs
from the 2 types of cardiac hypertrophy were clustered into 5
categories (Figure 4). In general, pathways involved in cardiac
muscle contraction and metabolism (Group I) were downregulat-
ed, whereas those involved in immune and cell cycle pathways
(Group II) were upregulated in PAH. These results are also
consistent with those of other microarray studies on PAH [56,57].
Among them, we are particularly interested in the leukocyte
migration pathway, which was significantly activated in PAH.
Recently, Damilano et al. [58] reported that PI3Kc in bone
marrow-derived leukocytes might play a critical role in leukocyte
infiltration in the myocardium and fibrotic remodeling during
PAH. They also suggested the importance of the interplay between
the heart and humoral immunity, in that bone marrow-derived
leukocytes augment fibrotic remodeling in the heart. In contrast,
one of the most striking findings of our study is that the
autoimmune-related pathways (Group III) were remarkably
suppressed during PHH. Interestingly, genes belonging to the
components of antigen presenting systems (e.g., Tap1, MHCI and
MHCII) were significantly suppressed during exercise. In fact, a
recent report showed that immunological stress caused by self-
antigens derived from the sudden accumulation of b1-adrenergic
receptor can induce the development of PAH in the heart [59].
Suppression of the antigen-presenting system during exercise may
prevent pathological progression during cardiac growth. Future
studies investigating the interplay between the heart and humoral
immunity are necessary. In contrast, pathways involved in signal
transduction (Group IV) showed no considerable differences in the
DEGs for both hypertrophy models, although AS is more obvious
in PHH. These results suggest that exercise provides a more
efficient means of signal transduction via AS rather than DEGs. It
is interesting to note that the pathways related to heart diseases
(Group V) were more sensitive to PAH than PHH with respect to
both DEGs and AS, implying that there are significant common
pathways for heart diseases.
Conclusion
RNA-Seq is a revolutionary technology that overcomes the
limitations posed by microarray methods. Using RNA-Seq, we
found not only DEGs but also different AS patterns during the
progression of hypertrophy. These are important issues in the
study of cardiac diseases. As exemplified by the unique qualitative
changes in the various pathways, some critical domains are likely
to be modified via AS without quantitative regulations. Taken
together, these findings show the unique transcriptomic signatures
of PAH and PHH. In turn, this provides a comprehensive
understanding of the pathogenesis of PAH at both quantitative
and qualitative levels.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Gwangju Institute
of Science and Technology Animal Care and Use Committee
(Permit number: GIST-2009-14).
Animal models
8 weeks old male (C57BL/6J) mice (body weight 28–33 g)
purchased from SLC Japan were used in all studies.
Pathological hypertrophy. Cardiac hypertrophy was
induced by TAC operation under anesthesia with intraperitoneal
injection of avertin, 2-2-2 tribromoethanol (Sigma, St. Louis, MO)
dissolved in tert-amyl alcohol (Sigma, St. Louis, MO). The
procedure of operation was followed as previously described [14].
As a control group, sham operation (same procedure except for
tying) was done. 1 week after operation, mice were sacrificed, and
hearts were removed, and then stored in deep freezer at 280uC
before RNA extraction.
Physiological hypertrophy. For chronic exercise training,
mice swam in water tanks for 4 weeks as described previously [12].
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by at least 4 hrs. The duration of exercise was increased in 10-min
increments daily, reaching 90 min, twice daily, by the middle of
the second week. This duration of exercise was maintained until 4
weeks. Trained mice were sacrificed and dissected 24 hrs after the
last training session to exclude any acute effect of exercise.
Dissected hearts were frozen and then stored in deep freezer at
280uC before RNA extraction.
RNA preparation
Mouse hearts were snap frozen in liquid nitrogen, stores at
280uC, and homogenized in liquid nitrogen using a mortar and
pestle. Approximately 450–700 mg of grinded whole mouse heart
was used for extraction of total RNA with 1 ml Trizol ReagentH
(Invitrogen, Carlsbad, CA) following the manufacturer’s instruc-
tions. The quality of total RNA was examined by standard RNA
chip on by Experion (Bio-Rad Laboratories, Hercules, CA)
according to the manufacture’s protocol.
Quantitative real-time PCR (qRT-PCR) and reverse-
transcriptional PCR (RT-PCR)
First-strand cDNA was synthesized from 2 mg of total RNA with
Random hexamer using OmniscriptH reverse transcription (Qia-
gen, Valencia, CA) according to the manufacturer’s instruction.
qRT-PCR assays were followed as previously described [60].
Briefly, qRT-PCR assays were performed using SYBRH Premix
Ex TaqTM (TaKaRa, Japan) under the following two-step
conditions: denaturation at 95uC for 5 seconds; and annealing
and extension at 60uC for 40 seconds, for a total of 40 cycles. The
18S transcript was used as an endogenous reference to assess the
relative level of mRNA transcript.
RT-PCR assays were performed on a TAKARA thermal cycler
TP600 (TaKaRa, Japan) using nTaq-HOT DNA polymerase
(Enzynomics, Daejeon, South Korea) under the following 3 step
conditions: denaturation at 94uC for 30 s, annealing at 55–60uC
for 30 s and extension at 72uC for 40 s with total 30–35 cycles.
cDNA library preparation for RNA-Seq
Selection of poly(A) mRNA from total RNA was performed
using Sera-Mag Magnetic Oligo(dT) Beads (Illumina, San Diego,
CA) according to the manufacturer’s protocol.
100 ng of mRNA was then used as template for cDNA
synthesis. Libraries were prepared according to instructions for
mRNA sample preparation kit (Illumina, San Diego, CA). 7 pM of
adaptor-ligated DNA was hybridized to the flow cell. DNA clusters
were generated using the Illumina cluster station, followed by 38
cycles of sequencing on the Illumina Genome Analyzer, in
accordance with the manufacturer’s protocols.
Data processing
The reads obtained by RNA-Seq were compiled using
manufacturer-provided pipeline software (Version 1.6). The reads
were then aligned onto the mm9 mouse chromosome using
Illumina built-in software ELAND2. Only uniquely mapped reads
with less than two mismatches were used. The exon coordinates
were downloaded from UCSC and analyzed using Illumina
supplied software CASAVA.
Microarray Analysis
Microarray analysis was performed on 100 ng of total RNA
samples (DNA link, South Korea) using the Mouse Gene 1.0 ST array
(Affymetrix, Foster City, CA). Generation of Labeled cDNA and
processing of Mouse Gene 1.0 ST array was performed according to
the Affymetrix standard protocol. After staining, intensities were
determined with a GeneChip scanner 3000 (Affymetrix, Foster City,
CA), controlled by GCOS Affymetrix software.
Differential Expression Analysis
For the DEG analysis, RPKM values of the genes having $2
RPKM were analyzed among sham vs. TAC-operated or
sedentary vs. exercise-trained mice by Student’s t-test (n=3 for
each animal models). For the comparison to microarray, RPKM
values of RNA-Seq were converted to logarithmic value of RPKB
to help the efficient comparison with the logarithmic value of
intensity of Affymetrix chips. For microarray, the expressional
intensities across 6 samples were normalized by RMA (Robust
Multi-array Average) and logarithmic scaled intensities were
further analyzed through Student’s t-test. In both methods,
differentially expressed genes were identified with the significance
values of p,0.05 and higher than 1.5 fold change.
AS Analysis
Alternative variants were analyzed based on the reads mapped
onto the pre-defined exons based on RefSeq structures. The
number of reads for each exon was used for the analyses and the
exons with less than 10 RPKM values were discarded to reduce
false positives. Fisher’s exact test (p,0.05) and Bayesian error rate
[61] (e#0.1) were used to determine the exon exclusion/inclusion.
Exon variants were then compared to knownAlt track of UCSC
database. Great enrichment of the specific exons in TAC or
exercise samples was considered as exon inclusion, and the
significant enrichment of sham-operated or sedentary samples was
considered as exon exclusion. For isoform analysis, we applied
NEUMA with default parameter for 36-bp single-end reads based
on UCSC gene structure [38].
Enriched Motif Analysis
The enrichment of motifs was analysis for 1,000 bp upstream of
genes. For this, the upstream sequences were obtained from
UCSC database [62]. Given the upstream sequences, we utilized
MEME suite to identify the enriched motifs of which width are
ranging 10,12 bps [18,63]. Occurrence of a single motif was
counted only once for each upstream and reverse complemented
motif was not considered. Predicted motifs were further compared
against a database of known motifs using TOMTOM [64].
Enriched KEGG pathway analysis
The enrichment of DEGs for IPA and KEGG pathways was
analyzed through Fisher’s exact test (p,0.05) as follows.
Pk(X§q)~
X n
i~q
p
i
  N{p
n{i
  
N
n
  
where N is the total number of genes mapped onto the entire
KEGG pathways,n is the number of genes mapped onto the
KEGG pathway of interest,p is the total number of DEGs or
splicing variants mapped onto the entire KEGG pathways, q is the
number of DEGs or splicing variants mapped onto the KEGG
pathway of interest.
Data accessibility
The RNA-Seq data from this study have been deposited in the
EBI ArrayExpress (http://www.ebi.2ac.uk/arrayexpress/) under
accession no. E-MTAB-727.
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Figure S1 Development of cardiac hypertrophy. (A) Body
weight (BW), heart weight (HW), and heart weight/body weight
ratio (HW/BW) at 1 week after TAC operation or at 4 weeks after
initiation of exercise training. The average values are shown with
standard deviation (N=3). TAC, transverse aortic constriction.
**p,0.01 (TAC vs. Sham).
{{p,0.01 (Exercise vs. Sedentary). (B)
Expression levels of hypertrophic markers in mice models. The
differential expressions of the hypertrophic markers were validated
using qRT-PCR. All the hypertrophic markers were differentially
expressed in TAC-operated mice models whereas only 2 markers
(Nppa and Acta1) were differentially expressed in exercise-trained
mice models. Statistically significant at
*p,0.05,
**p,0.01 and
***p,0.001. Bars represent means 6 SD.
(TIF)
Figure S2 Quality assessment of high-throughput data
from RNA-Seq. Reproducibility among the biological replicates
derived by (A) RNA-Seq and (B) microarray. To validate
experimental reproducibility, linear regression of R-square (R
2)
was calculated among all the replicates derived from RNA-Seq or
microarray. The slight expressional differences encountered at the
extremely low-level reads could be significantly exaggerated by
RPKM normalization. For RNA-Seq, we defined the expression at
$2 RPKM. (C) Technological comparison of gene expression
between RNA-Seq and microarray. The same mRNAs were used
for both RNA-Seq and microarray studies. R
2 was calculated for
each replicates. RPKM values of RNA-Seq were transformed into
log2 scaled RPKB (reads per kilobase per billion mapped reads) to
produce a comparable scale. Slightly skewed patterns were
observed at low- or high-level expression for all comparisons,
suggesting non-linear sensitivity or limited detection capacity of
the microarray method at low or high levels of expression.
(TIF)
Figure S3 Comparison of differentially expressed genes
(DEGs) derived from RNA-Seq and microarray. (A) A dot
plot of log fold changes of DEGs obtained by RNA-Seq and
microarray is shown. The DEG groups are categorized as: 1)
‘‘Common DEGs’’ showing relatively similar expression patterns
between the 2 methods (violet dots) 2) ‘‘RNA-Seq specific DEGs’’
(red dots) and 3) ‘‘Microarray specific DEGs’’ (blue dots). (B) Venn
diagram for DEGs derived from RNA-Seq and microarray for
PAH (Student t-test, p,0.05, log1.5|fold change|$1). (C–E)
Experimental superiority of RNA-Seq over microarray was
verified by qRT-PCR. For each series of experiment, the same
mRNAs were used for 51 genes tested. Note that the expression
profiles obtained by RNA-Seq were significantly more coherent to
those obtained by qRT-PCR in PAH (R
2=0.86) (C) and in PHH
(R
2=0.89) (D) than those obtained by microarray (R
2=0.69) (E).
(TIF)
Figure S4 Network of the genes oppositely regulated in
PAH and PHH. (A) Top-scoring network derived from 52 genes
oppositely regulated in PAH and PHH. The red color indicates
up-regulated genes in PAH. All genes showing increased
expression in the network were significantly down-regulated in
PHH. (B) The predicted motifs in the 1,000 bp upstream of the 52
oppositely regulated genes. The bottom motifs were predicted by
MEME and the motifs above are the consensus ones for MAZ.
Degree of expression of Maz is shown in the order of Sham (Sh),
TAC (T), Se (Sedentary) and E (exercise).
(TIF)
Figure S5 Summary data of the alternative splicing
patterns for PAH and PHH. (A) Summary of the method to
detect alternative exons by RNA-Seq. Significant exon variants
were identified from 182,627 exons in the UCSC database by
filtering with Bayesian probability (e#0.1), Fisher’s exact test
(p,0.05), and knownAlt tracks from the UCSC database. (B, C)
Pie charts representing types of exon variants for (B) PAH and (C)
PHH. The types of alternative splicing for the exon variants in
hypertrophy were examined on the basis of known UCSC
‘knownAlt’ tracks. The most abundant AS types were grouped
as alternative promoters, cassette exons and bleeding exons for
both types of hypertrophy.
(TIF)
Table S1 Summary of read number. Given 13,20 million
reads, 7,11 million reads were mapped to known genes in mm9
mouse genomes. Only the reads that have $2 RPKM were
selected for ‘‘expressed genes for each models.
(DOC)
Table S2 The primer sets for amplification of exon
variants shown in Figure 4. F and R represent forward and
reverse, respectively.
(DOC)
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